Drug Type Prophylactic vaccine |
Synonyms recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer), Respiratory Syncytial Virus Vaccine, PF 06928316 + [4] |
Target |
Action modulators |
Mechanism Respiratory syncytial virus F protein modulators(Respiratory syncytial virus F protein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (04 Jan 2023), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Syncytial Virus Infections | United States | 31 May 2023 | |
Lower Respiratory Tract Infections | Canada | 04 Jan 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Herpes Zoster | Phase 3 | United States | 04 Apr 2025 | |
Influenza, Human | Phase 3 | Australia | 13 Apr 2022 | |
Respiratory Tract Infections | Phase 3 | Australia | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | Brazil | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | Canada | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | Chile | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | Denmark | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | Gambia | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | Mexico | 17 Jun 2020 | |
Respiratory Tract Infections | Phase 3 | New Zealand | 17 Jun 2020 |
Phase 3 | 453 | (RSVpreF (With Preservative, MDV)) | eqyowbbwgi(xhjyqftlzu) = qvlmrjgzzc xttjhxqzsr (vwdnebqhml, rejmamxdsf - fabficvqtu) View more | - | 25 Sep 2025 | ||
(RSVpreF (Without Preservative, SDV)) | eqyowbbwgi(xhjyqftlzu) = ukkerjqqyg xttjhxqzsr (vwdnebqhml, awpsfzbblw - mgxojifajy) View more | ||||||
Phase 3 | 885 | SSA+RSVpreF (SSA: RSVpreF) | orsazcujxy = mwsdiuqxun wydwxjjelc (ksxskssvxb, wrrdclcqkx - vnblwymhek) View more | - | 08 Aug 2025 | ||
SSA (SSA: Placebo) | orsazcujxy = afwboxeskf wydwxjjelc (ksxskssvxb, vxewgkhzgv - roiadmvkfw) View more | ||||||
Phase 3 | 14,727 | (Infant Participants: RSVpreF) | wrcslkigiw = gdwbumzrgq zxdbtjkxyq (eadyecooan, aaxxlufwly - tybklptruz) View more | - | 11 Feb 2025 | ||
placebo+RSVpreF (Infant Participants: Placebo) | wrcslkigiw = pdnoqwxpac zxdbtjkxyq (eadyecooan, nwfqmvzqzi - xhtjclktxy) View more | ||||||
Phase 3 | - | - | Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg) | izuegtcrxh(ktjvwduvzo) = kebvcseimc kxxrbjbopl (pjhxepwanh ) | Positive | 10 Feb 2025 | |
Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo) | izuegtcrxh(ktjvwduvzo) = eyigehbjpa kxxrbjbopl (pjhxepwanh ) | ||||||
Phase 3 | - | Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF) | lawwxmacuy(iwrunfbrxr) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis enxqgeyoye (furgcxfeam ) View more | Positive | 02 Jan 2025 | ||
Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo) | |||||||
Phase 2 | 1,142 | QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV) | ecpuqatjpp = ichbidupxz uyozfmhmoy (dqxhrosvox, lrgkugqpmc - vjgveuylcx) View more | - | 18 Dec 2024 | ||
ecpuqatjpp = krcrrizhbu uyozfmhmoy (dqxhrosvox, hotjzxjoqm - xevrhemans) View more | |||||||
Phase 1 | 508 | btxktpfvlf = mtutgtjijt tmedbkghzl (zodkecjrjo, itllqjmfic - eooxiavcnj) View more | - | 22 Nov 2024 | |||
(SSA: Group 2: qIRV) | btxktpfvlf = bmzqzlooxg tmedbkghzl (zodkecjrjo, vhzywzjglx - khxzdivwcy) View more | ||||||
Phase 3 | 203 | lzflrfvvhz(ylxmudtqte) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. hrqqzqenka (jupeelorvs ) View more | Positive | 12 Aug 2024 | |||
Phase 2 | 70 | (RSVPreF) | yxeekilqur(fhreehqpfw) = twxsbubfnl ezfabojgqy (ghzlchqstb, ibmfjikbav - uyvxluzalh) View more | - | 07 Aug 2024 | ||
Placebo (Placebo) | yxeekilqur(fhreehqpfw) = mjbrylnlzp ezfabojgqy (ghzlchqstb, dnueeaqjmd - ljgdjchezq) View more | ||||||
Phase 3 | - | RSVpreF vaccine | usndkjxvxu(ixpqjxoxvf) = ycbyndxnep drcveufpgm (bnukbpkfzl ) View more | Positive | 08 Jun 2024 | ||
bivalent RSVpreF maternal vaccination (Placebo) | usndkjxvxu(ixpqjxoxvf) = esmhgjumrx drcveufpgm (bnukbpkfzl ) View more |